CANCER HEALTH
The Food and Drug Administration (FDA) recently approved azacitidine (Vidaza) for pediatric patients 1 month and older with newly diagnosed juvenile myelomonocytic leukemia (JMML). JMML is an uncommon blood cancer that accounts for 1–2% of all childhood leukemia cases and most often occurs in infants and children younger than…
